1-6 of 6
Thomas Bachelot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1582.
https://doi.org/10.1158/1078-0432.CCR-21-0193
Published: 01 March 2021
View article titled, Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer
Open the PDF for Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer in another window
Journal Articles

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

Sara M. Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa Nardi, Uz Stammberger, Ahmed M. Abdelhady, Shiling Ruan, Soo Chin Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 418–428.
https://doi.org/10.1158/1078-0432.CCR-20-0645
Published: 19 January 2021
View article titled, Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast Cancer
Open the PDF for Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (20): 5310–5319.
https://doi.org/10.1158/1078-0432.CCR-20-1764
Published: 15 October 2020
View article titled, A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Open the PDF for A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Jean-Yves Pierga, Thierry Petit, Christelle Lévy, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Jacques Bonneterre, Juana Hernandez, François-Clément Bidard, Patrice Viens
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1298–1304.
https://doi.org/10.1158/1078-0432.CCR-14-1705
Published: 12 March 2015
View article titled, Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2<sup>+</sup> Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data
Open the PDF for Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2<sup>+</sup> Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data in another window
Journal Articles

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Fabrice André, Thomas Bachelot, Mario Campone, Florence Dalenc, Jose M. Perez-Garcia, Sara A. Hurvitz, Nicholas Turner, Hope Rugo, John W. Smith, Stephanie Deudon, Michael Shi, Yong Zhang, Andrea Kay, Diana Graus Porta, Alejandro Yovine, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3693–3702.
https://doi.org/10.1158/1078-0432.CCR-13-0190
Published: 30 June 2013
View article titled, Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
Open the PDF for Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

Isabelle Treilleux, Jean-Yves Blay, Nathalie Bendriss-Vermare, Isabelle Ray-Coquard, Thomas Bachelot, Jean-Paul Guastalla, Alain Bremond, Sophie Goddard, Jean-Jacques Pin, Clarisse Barthelemy-Dubois, Serge Lebecque
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7466–7474.
https://doi.org/10.1158/1078-0432.CCR-04-0684
Published: 29 November 2004
View article titled, Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Open the PDF for Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer in another window